Celcuity (CELC) Scheduled to Post Earnings on Wednesday

Celcuity (NASDAQ:CELC - Get Free Report) will post its quarterly earnings results after the market closes on Wednesday, May 15th. Analysts expect Celcuity to post earnings of ($0.70) per share for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings results on Wednesday, March 27th. The company reported ($0.65) earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $0.06. On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Celcuity Trading Down 1.5 %

Shares of Celcuity stock traded down $0.26 during trading hours on Thursday, hitting $17.35. The company's stock had a trading volume of 82,169 shares, compared to its average volume of 220,027. The business has a fifty day moving average of $18.05 and a 200 day moving average of $15.32. Celcuity has a 1-year low of $8.39 and a 1-year high of $22.19. The company has a quick ratio of 13.43, a current ratio of 13.43 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $528.36 million, a PE ratio of -6.45 and a beta of 0.87.

Analyst Upgrades and Downgrades

Several research analysts have commented on CELC shares. Needham & Company LLC reissued a "buy" rating and issued a $24.00 price objective on shares of Celcuity in a research report on Friday, April 12th. Craig Hallum boosted their price target on Celcuity from $20.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 28th. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a research report on Thursday, March 28th. Finally, Stifel Nicolaus started coverage on shares of Celcuity in a research note on Thursday, February 22nd. They set a "buy" rating and a $40.00 price objective on the stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.